Pharming Group N.V. (AMS:PHARM)
1.710
-0.070 (-3.93%)
At close: Jan 28, 2026
Pharming Group Revenue
Pharming Group had revenue of $97.30M USD in the quarter ending September 30, 2025, with 30.00% growth. In the year 2024, Pharming Group had annual revenue of $297.20M with 21.15% growth.
Revenue
$297.20M
Revenue Growth
+21.15%
P/S Ratio
3.95
Revenue / Employee
$735.64K
Employees
404
Market Cap
1.22B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 297.20M | 51.88M | 21.15% |
| Dec 31, 2023 | 245.32M | 39.69M | 19.30% |
| Dec 31, 2022 | 205.62M | 6.75M | 3.39% |
| Dec 31, 2021 | 198.87M | -13.30M | -6.27% |
| Dec 31, 2020 | 212.17M | 22.53M | 11.88% |
| Dec 31, 2019 | 189.64M | 34.36M | 22.12% |
| Dec 31, 2018 | 155.29M | 47.75M | 44.40% |
| Dec 31, 2017 | 107.54M | 90.83M | 543.88% |
| Dec 31, 2016 | 16.70M | 4.94M | 42.05% |
| Dec 31, 2015 | 11.76M | -13.88M | -54.13% |
| Dec 31, 2014 | 25.63M | 16.22M | 172.36% |
| Dec 31, 2013 | 9.41M | -4.59M | -32.77% |
| Dec 31, 2012 | 14.00M | 10.12M | 260.60% |
| Dec 31, 2011 | 3.88M | 2.41M | 163.98% |
| Dec 31, 2010 | 1.47M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Havas | 2.91B |
| Fugro | 2.09B |
| Acomo | 1.45B |
| AMG Critical Materials | 1.38B |
| Corbion | 1.30B |
| OCI N.V. | 879.60M |
| Flow Traders | 766.68M |
| TomTom | 565.73M |
Pharming Group News
- 7 days ago - Original-Research: Pharming Group NV (von First Berlin Equity Research GmbH):... • news - Onvista
- 20 days ago - Pharming Projects 27% Revenue Growth In 2025, Surpassing Prior Guidance, Driven By RUCONEST, Joenja - Nasdaq
- 20 days ago - Pharming Group reports preliminary 2025 revenues and announces Investor Day - GlobeNewsWire
- 7 weeks ago - Pharming Group to participate in Oppenheimer Movers in Rare Disease Summit - GlobeNewsWire
- 2 months ago - Wall Street Analysts Believe Pharming Group (PHAR) Could Rally 81.71%: Here's is How to Trade - Nasdaq
- 2 months ago - Pharming Group N.V. (PHAR) Presents at Jefferies London Healthcare Conference 2025 - Slideshow - Seeking Alpha
- 2 months ago - Pharming Group Posts Upbeat Q3 Results, Joins On Holding, BigBear.ai Holdings And Other Big Stocks Moving Higher On Wednesday - Benzinga
- 2 months ago - Earnings Estimates Moving Higher for Pharming Group (PHAR): Time to Buy? - Nasdaq